Unlocking the Epigenome for Acute Liver Disease Clinical Research

Epigenetic therapies are emerging as a promising new approach in modern medicine. Unlike traditional treatments that target specific proteins or pathways, epigenetic approaches work by modulating gene expression without altering the underlying DNA sequence. This strategy leverages the complex network of the epigenome that dictates which genes are turned on or off. For instance, while DNA represents the essential “genetic hardware,” the vast majority of the nucleus is occupied by chromatin-associated proteins — the dynamic “software” that runs gene expression.

This insight is important given that recent studies have shown that aberrant DNA methylation is a common feature in severe diseases — for example, abnormal methylation patterns have been identified in over 70% of hepatocellular carcinoma cases, and similar high prevalence rates are observed in other advanced cancers — pointing out the critical role of epigenetic modifications in disease progression.

In a recent discussion with James E. Brown, DVM, CEO of DURECT, we gained valuable insights into the challenges and breakthroughs defining the clinical research landscape for epigenetic-based therapies. DURECT’s work has garnered significant attention, including notable milestones such as receiving Breakthrough Therapy designation from the FDA and the publication of Phase IIb data in NEJM Evidence in patients with alcohol-associated hepatitis (AH).

AH is an acute form of liver inflammation and damage resulting from excessive alcohol consumption, characterized by rapid deterioration in liver function and high mortality rates of approximately 30% at 90 days. AH presents a particularly challenging clinical scenario due to its unpredictable progression and the limited efficacy of supportive care, making it an urgent area for therapeutic development.

With an innovative approach that uses the potential of epigenetic modulation, DURECT is aiming to change how we treat life-threatening conditions like AH. These advances, combined with strategic regulatory and clinical collaborations, show the promise of epigenetic research in redefining therapies for acute liver disease.

Xtalks Clinical Edge™: Issue 4 — DURECT’s Approach to Acute Liver Disease Clinical Research

Xtalks Clinical Edge™ is a magazine for clinical research professionals and all who want to be informed about the latest trends and happenings in clinical trials. This magazine immerses you in a world where industry leaders, patient advocates and top researchers converge to provide the most insightful perspectives on clinical trials.